Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 0.64 |
| ▸ | CA1 | P00915 | 12/20 | 0.64 |
| ▸ | CA9 | Q16790 | 11/20 | 0.64 |
| ▸ | CA12 | O43570 | 11/20 | 0.64 |
| ▸ | CA5A | P35218 | 7/20 | 0.64 |
| ▸ | CA7 | P43166 | 7/20 | 0.64 |
| ▸ | CA5B | Q9Y2D0 | 7/20 | 0.64 |
| ▸ | CA6 | P23280 | 5/20 | 0.64 |
| ▸ | CA3 | P07451 | 3/20 | 0.64 |
| ▸ | CA4 | P22748 | 5/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.59 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.59 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.56 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL202948 | 0.85 | CA2 (0.81) | CA2CA1CA9CA12CA5A | |
| SCHEMBL2376239 | 0.85 | ENPP2 (0.72) | ENPP2 | |
| SCHEMBL30232451 | 0.79 | CA2 (0.58) | CA2CA1CA9CA12CA5A | |
| SCHEMBL14264259 | 0.79 | CA1 (0.76) | CA2CA1CA9CA12CA5A | |
| SCHEMBL7676697 | 0.78 | CA2 (0.62) | CA2CA1CA9CA12CA5A | |
| P-Toluenesulfonamide SCHEMBL1331323 | 0.78 | CA2 (1.00) | CA2CA1CA9CA12CA5A | |
| P-Toluenesulfonamide SCHEMBL7370 | 0.78 | CA2 (1.00) | CA2CA1CA9CA12CA5A | |
| SCHEMBL55092 | 0.78 | TSHR (0.62) | CA2CA1CA9CA12CA5A | |
| P-Toluenesulfonamide SCHEMBL31527821 | 0.78 | CA2 (1.00) | CA2CA1CA9CA12CA5A | |
| SCHEMBL10300269 | 0.77 | PTGS2 (0.62) | CA2CA9CA12ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240409508-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO, INC. | 2024-12-12 | — | — | US | disclosed |
| CN-118791407-A | Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives | 奥索生物公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-118638096-A | Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives | 奥索生物公司 | 2024-09-13 | — | — | CN | disclosed |
| US-12049439-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| CN-112204008-B | Sulfonylaminobenzamides and sulfonylaminobenzamide derivatives | 奥索生物公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-3796975-B1 | SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| US-20230104936-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-2258356-B1 | CHEMICAL COMPOUNDS HAVING ANTIVIRAL ACTIVITY AGAINST DENGUE VIRUS AND OTHER FLAVIVIRUSES | CT INGENIERIA GENETICA BIOTECNOLOGIA (CU) | 2017-09-27 | — | — | EP | disclosed |
| US-7001917-B2 | Pyrazole compounds as anti-inflammatory and analgesic agents | WARNER LAMBERT COMPANY LLC (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1156803-A4 | LACTAM INHIBITORS OF FXa AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | HIRANO MISATO (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-1301480-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002006223-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-01-24 | — | — | WO | disclosed |
| EP-1156803-A1 | LACTAM INHIBITORS OF FXa AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6297233-B1 | Lactam inhibitors of FXa and method | BRISTOL-MYERS SQUIBB COMPANY | 2001-10-02 | — | — | US | disclosed |
| WO-2000047207-A1 | LACTAM INHIBITORS OF FXa AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-08-17 | — | — | WO | disclosed |
| US-4690934-A | N-phenylsulfonylisonicotinamide derivatives and their use as fungicides or bactericides | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1987-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | PTGER1, PTGS1, PTGIR | CA2 230/4885CA1 1837/4885CA9 1762/4885 |
| US-12049439-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | CA2 1775/4885CA1 2349/4885CA9 1512/4885 |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | CA2 698/4885CA1 2501/4885CA9 1594/4885 |
| US-20230104936-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | CA2 294/4885CA1 1974/4885CA9 3168/4885 |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | NR3C2, NR5A1, SRD5A2 | CA2 3086/4885CA1 3778/4885CA9 1910/4885 |
| US-20240409508-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | CA2 1775/4885CA1 2349/4885CA9 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.